Cybin presents CYB003 preclinical data at ACNP

Cybin "announced that the company presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology, ACNP, annual meeting taking place December 4-7, 2022, in Phoenix, Arizona. The data presented, including new pharmacokinetics findings, further strengthen the therapeutic profile of CYB003 as a novel treatment for major depressive disorder, or MDD. "These new findings demonstrate the unique PK properties of CYB003 compared with classical psilocybin and further supports our ongoing first-in-human Phase 1/2a clinical trial evaluating CYB003 for the treatment of MDD," said Amir Inamdar, MBBS, DNB, Cybin’s Chief Medical Officer.